Cardiovascular disease in diabetes mellitus type 2: A potential role for novel cardiovascular risk factors

Current Opinion in Lipidology

Volumn 11, Issue 5, 2000, Pages 519-528

  Hayden, John M ^a   Reaven, Peter D ^a  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; ENDOTHELIUM CELL; GLYCATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ARTERIOSCLEROSIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION MEDIATORS; LIPOPROTEINS, LDL; MODELS, BIOLOGICAL; MONOCYTES; OXIDATIVE STRESS; RISK FACTORS;

EID: 0033779967     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200010000-00010     Document Type: Review

References (127)

1. Banting lecture 1988. Role of insulin resistance in human disease
2. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X
3. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
4. Diabetic dyslipidemia
5. Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma
6. Nonoxidative modifications of lipoproteins in atherogenesis
7. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase
8. Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats
9. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein
10. Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy
11. Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology
12. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma
13. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM
14. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity
15. Hydroperoxides in plasma are reduced by intensified insulin treatment. A randomized controlled study of IDDM patients with microalbuminuria
16. Lipid peroxidation in type 2 normolipidemic diabetic patients
17. Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance, and NIDDM
18. Postprandial low-density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples
19. Electronegative low density lipoprotein subform (LDL-) is increased in type 2 (non-insulin-dependent) microalbuminuric diabetic patients and is closely associated with LDL susceptibility to oxidation
20. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation
21. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation
22. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma
23. Autoantibody titers to malondialdehyde modified LDL correlates with extent of coronary artery disease
24. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis
25. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis
26. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk
27. Is oxidized low-density lipoprotein present in vivo?
28. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus
29. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus
30. Levels of antibodies to an epitope of oxidized LDL and risk of myocardial infarction (MI) in the Physicians' Health Study
31. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM
32. Autoantibodies against oxidized LDL and endothelium-dependent vasodilation in insulin-dependent diabetes mellitus
33. The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus
34. Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications
35. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: A nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study
36. F2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: Effects of vitamin E
37. Increased formation of distinct F2 isoprostanes in hypercholesterolemia
38. The isoprostane, 8-epi-PGF2 alpha, is accumulated in coronary arteries isolated from patients with coronary heart disease
39. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice
40. Formation of an F2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors
41. Plasma 8-epi-PGF-2alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus
42. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
43. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits
44. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs
45. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
46. 'Autoxidative glycosylation': Free radicals and glycation theory
47. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
48. Aminoguanidine has an antiatherogenic effect in the cholesterol-fed rabbit
49. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: Relationship to tissue AGEs
50. Relative contribution of insulin and its precursors to fibrinogen and PAl-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS)
51. The relationships between insulin and plasminogen activator inhibitor 1 levels: Assessment in groups of subjects with dyslipidaemia and hypertension
52. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects
53. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group
54. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue
55. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus
56. A prospective evaluation of atherosclerotic risk factors and hypercoagulability in young adults with premature lower extremity atherosclerosis
57. Association of fibrinolytic parameters with early atherosclerosis. The Alherosclerosis Risk in Communities (ARIC) Study
58. Proinsulin and insulin concentrations in relation to carotid wall thickness. Insulin Resistance Atheresclerosis Study
59. Increased fibrin turnover and high PAl-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group
60. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor
61. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities
62. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture
63. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells
64. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB-dependent fashion
65. Native low density lipoprotein-induced calcium transients trigger VCAM-1 and E-selectin expression in cultured human vascular endothelial cells
66. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis
67. Soluble I-selectin is present in human plasma at high levels and retains functional activity
68. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carolid atherosclerosis
69. Elevated serum concentrations of soluble adhesion molecules in coronary artery disease and acute myocardial infarction
70. A longitudinal prospective study of soluble adhesion molecules in acute stroke
71. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis
72. Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits
73. Endothelial adhesion molecule expression is enhanced in the aorta and internal mammary artery of diabetic patients
74. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control
75. Hyperglycemia-induced circulating ICAM-1 increase in diabetes meltitus: The possible role of oxidative stress
76. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes
77. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment
78. The incidence and characteristics of silent cerebral infarction in elderly diabetic patients: Association with serum-soluble adhesion molecules
79. Circulating adhesion molecules in humans: Role of hyperglycemia and hyperinsulinemia
80. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells
81. Roles for insulin receptor, Pl3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells
82. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: A specific vascular action of insulin
83. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance
84. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM
85. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance
86. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance
87. Basal nitric oxide production is not reduced in patients with noninsulin-dependent diabetes mellitus
88. Review of alterations in endothelial nitric oxide production in diabetes: Protective role of arginine on endothelial dysfunction
89. Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: Importance of disease duration
90. Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia
91. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
92. Binding of monocytes from normolipidemic hyperglycemic patients with type 1 diabetes to endothelial cells is increased in vitro
93. Adherence of mononuclear cells to endothelium in vitro is increased in patients with NIDDM
94. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment
95. Circulating monocytes are activated in newly diagnosed type 1 diabetes mellitus patients
96. Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients
97. Synthesis and secretion of tumour necrosis factor-alpha by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts
98. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging
99. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation
100. Advanced glycosylated end products activate the functions of cell adhesion molecules on lymphoid cells
101. The advanced glycation endproduct pentosidine and monocyte activation in uremia
102. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
103. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
104. Fibrin as a factor in atherogenesis
105. Measuring plasma fibrinogen to predict stroke and myocardial infarction: An update
106. Haemostatic measures in type 2 diabetic patients with microalbuminuria
107. Plasma fibrinogen: A new factor of the metabolic syndrome. A population-based study
108. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes
109. Hyperfibrinogenemia: A major determinant of vascular complications in diabetes
110. Reducing the burden of diabetes: Managing cardiovascular disease
111. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
112. Modulation of human monocyte chemotaxis and procoagulant activity by human C-reactive protein (CRP)
113. Enhancement of human peripheral blood monocyte respiratory burst activity by aggregated C-reactive protein
114. Complement and atherogenesis: Binding of CRP to degraded, nonoxidized LDL enhances complement activation
115. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project
116. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
117. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial
118. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease
119. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
120. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women
121. Body mass index, diabetes, and C-reactive protein among US adults
122. Von Willebrand Factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: The Hoorn Study
123. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
124. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
125. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus
126. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects
127. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with type II diabetes